Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

CAMBRIDGE, Mass., Jan. 02, 2024 -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Japan ,United States ,Massachusetts ,Sath Shukla ,Lora Grassilli ,Ted Jenkins ,Exchange Commission ,Zeno Group ,Spero Therapeutics Inc ,Development Authority ,Health Media Relations ,Nasdaq ,Drug Administration ,Meiji Seika Pharma Co ,Administration For Strategic Preparedness ,Human Services ,Globenewswire Inc ,Tebipenem Hbr Research ,Biomedical Advanced Research ,Us Department Of Health ,Meiji Seika Pharma ,Qualified Infectious Disease Product ,Fast Track ,Strategic Preparedness ,Relations Contact ,Investor Relations ,Health Media ,Markets ,